| Kelly L Costello, MD | |
|
401 N 17th St, Suite 203, Allentown, PA 18104-5034 | |
| (610) 821-4920 | |
| Not Available |
| Full Name | Kelly L Costello |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 401 N 17th St, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801828884 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD059048L (Pennsylvania) | Primary |
| Entity Name | Lehigh Valley Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457309650 PECOS PAC ID: 3072425123 Enrollment ID: O20040227000335 |
News Archive
In this video report, PBS NewsHour's "The Rundown" examines curable and preventable diseases such as measles and river blindness that countries are focusing more effort on fighting. Mark Eberhardt, a neglected tropical diseases expert at the CDC, and Stephen Cochi, a measles and polio expert from the CDC, "describe the diseases and why they still need attention."
Researchers at The University of Texas at San Antonio (UTSA) are surveying households in two San Antonio zip codes, 78230 and 78202, about their energy use, mobility and chronic health conditions. Once the survey is complete, the data will be combined with cell phone GPS data to improve the ability to predict energy demand through time at the neighborhood level.
Itamar Medical announced confirmation of PAT technology by several prestigious research groups. In light of scientific confirmation of PAT technology, Itamar Medical will now promote clinical use in the medical community for the prevention of cardiovascular disease.
They hope that the hormone, obestatin, which belongs to the same family ghrelin, which stimulates the appetite, may be a key to the fight against obesity.
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelly L Costello, MD Po Box 1754, Allentown, PA 18105-1754 Ph: () - | Kelly L Costello, MD 401 N 17th St, Suite 203, Allentown, PA 18104-5034 Ph: (610) 821-4920 |
News Archive
In this video report, PBS NewsHour's "The Rundown" examines curable and preventable diseases such as measles and river blindness that countries are focusing more effort on fighting. Mark Eberhardt, a neglected tropical diseases expert at the CDC, and Stephen Cochi, a measles and polio expert from the CDC, "describe the diseases and why they still need attention."
Researchers at The University of Texas at San Antonio (UTSA) are surveying households in two San Antonio zip codes, 78230 and 78202, about their energy use, mobility and chronic health conditions. Once the survey is complete, the data will be combined with cell phone GPS data to improve the ability to predict energy demand through time at the neighborhood level.
Itamar Medical announced confirmation of PAT technology by several prestigious research groups. In light of scientific confirmation of PAT technology, Itamar Medical will now promote clinical use in the medical community for the prevention of cardiovascular disease.
They hope that the hormone, obestatin, which belongs to the same family ghrelin, which stimulates the appetite, may be a key to the fight against obesity.
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.
› Verified 9 days ago
Dr. Ruchi Gupta, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 401 N 17th St, Suite 309, Allentown, PA 18104 Phone: 610-437-6687 | |
Dr. Douglas Mchale, DO Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1200 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 610-402-7712 Fax: 224-484-1306 | |
Dr. Sajani Jitendra Sukhadia, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1611 Pond Rd Ste 400, Allentown, PA 18104 Phone: 610-402-8000 | |
Dr. Heather Noreen Becker, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1200 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 610-402-9750 | |
Sara S Viessman, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1627 W Chew St, Suite 601, Allentown, PA 18102 Phone: 610-969-2555 | |
Paige Payne, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 450 Chew St Ste 203, Allentown, PA 18102 Phone: 484-503-3058 | |
Daniel Helmut Ublagger, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1200 S Cedar Crest Blvd Fl 6, Allentown, PA 18103 Phone: 610-402-7712 Fax: 484-224-1306 |